Key Takeaways
- • Rep. Steve Cohen (D-Tenn.) introduced the Public Health and Research Reforms in Controlled Substances Act, a bill proposing to revise major parts of the 1970 Controlled Substances Act, according to a Quiver Quantitative press release summary.
- • The bill would rework drug scheduling rules, remove weight-based mandatory minimum penalties, shift some authority to the Department of Health and Human Services, and expand research provisions.
- • The measure would begin reviews of about 30 substances, including fentanyl, morphine, methamphetamine, psilocybin and ibogaine, and would remove marijuana from the CSA.
- • The release states the bill would retain enforcement tools against major traffickers and create clearer research licensing rules; several drug-policy groups endorsed it.
Summary
Rep. Steve Cohen announced on October 29, 2026 that he has introduced the Public Health and Research Reforms in Controlled Substances Act, a proposal to revise major parts of the Controlled Substances Act (CSA) enacted in 1970. Cohen described the bill as an effort to update federal drug policy around "public health," "equal justice," and "scientific accuracy," and said it reflects a long-overdue review of federal drug law, according to the press release as summarized by Quiver Quantitative.
According to the release, the bill would rework federal drug scheduling rules and remove weight-based mandatory minimum penalties. It would also shift some authority to the Department of Health and Human Services and expand research provisions, including clearer licensing rules for controlled-substance research. The legislation would initiate reviews of roughly 30 substances, among them fentanyl, morphine, methamphetamine, psilocybin and ibogaine. It would also remove marijuana from the CSA.
The release says the measure would preserve enforcement tools against major drug traffickers. It was endorsed by several drug-policy groups, which the release did not name in the summary provided. The Quiver summary is an AI-generated digest of the press release, and the full text of the bill and any committee action were not available in the source material.
Cohen's political profile, as tracked by Quiver Quantitative, shows $0 in fundraising reported in a Q3 FEC filing dated October 15, 2026, $55.5K in spending, and $1.8M in cash on hand at the end of the filing period. Quiver estimates his net worth at $10.7M as of October 29, 2026, with approximately $3.9M in publicly traded assets it can track. The 2026 Tennessee's 9th Congressional District race, which Quiver rates "Solid R," has drawn roughly $13.6M in spending over the last two years, about $4.9M of it from outside PACs and Super PACs.
According to the release, the bill would rework federal drug scheduling rules and remove weight-based mandatory minimum penalties. It would also shift some authority to the Department of Health and Human Services and expand research provisions, including clearer licensing rules for controlled-substance research. The legislation would initiate reviews of roughly 30 substances, among them fentanyl, morphine, methamphetamine, psilocybin and ibogaine. It would also remove marijuana from the CSA.
The release says the measure would preserve enforcement tools against major drug traffickers. It was endorsed by several drug-policy groups, which the release did not name in the summary provided. The Quiver summary is an AI-generated digest of the press release, and the full text of the bill and any committee action were not available in the source material.
Cohen's political profile, as tracked by Quiver Quantitative, shows $0 in fundraising reported in a Q3 FEC filing dated October 15, 2026, $55.5K in spending, and $1.8M in cash on hand at the end of the filing period. Quiver estimates his net worth at $10.7M as of October 29, 2026, with approximately $3.9M in publicly traded assets it can track. The 2026 Tennessee's 9th Congressional District race, which Quiver rates "Solid R," has drawn roughly $13.6M in spending over the last two years, about $4.9M of it from outside PACs and Super PACs.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.